Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Beta-caryophyllene is a bicyclic sesquiterpene found in various essential oils, particularly clove oil, black pepper, and cannabis. Its use for epilepsy is supported by preliminary scientific evidence, mainly from preclinical studies. Beta-caryophyllene acts as a selective agonist of the cannabinoid receptor type 2 (CB2), which is involved in modulating inflammation and neuroprotection. Several animal studies have demonstrated that beta-caryophyllene can reduce seizure severity and frequency in rodent models of epilepsy. For example, a 2014 study published in "Epilepsy & Behavior" showed that beta-caryophyllene significantly decreased seizure activity in mice treated with pentylenetetrazole, a chemical used to induce seizures. The proposed mechanisms include anti-inflammatory effects, reduction of oxidative stress, and modulation of neuronal excitability through CB2 receptor activation. However, there are no large-scale clinical trials in humans to confirm efficacy or safety for epilepsy treatment. Thus, while the scientific rationale and animal data are promising, clinical validation is lacking. Beta-caryophyllene is not a standard or approved treatment for epilepsy, but it is being actively investigated in the context of cannabinoid-based therapies. At present, its use is supported by scientific evidence at the preclinical level, warranting further research to establish its therapeutic potential in humans.

More about beta caryophyllene
More about Epilepsy

Other ingredients used for Epilepsy

Other health conditions supported by beta caryophyllene

Products containing beta caryophyllene